Indications and uses
treats vaginal yeast infections relieves external itching and irritation due to a vaginal yeast infection
treats vaginal yeast infections relieves external itching and irritation due to a vaginal yeast infection
before using this product, read the enclosed educational brochure for complete directions and information adults and children 12 years of age and over: vaginal cream: insert one applicatorful of cream into the vagina at bedtime for 7 days in a row. Wash applicator after each use. external cream: use the same tube of cream if you have itching and irritation on the skin outside the vagina. Squeeze a small amount of ...
Clotrimazole, USP 1% (50 mg in each applicatorful)
Clotrimazole, USP 1% (external cream)
Vaginal antifungal
Vaginal antifungal
For vaginal use only
if you have never had a vaginal yeast infection diagnosed by a doctor
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
benzyl alcohol, cetostearyl alcohol, cetyl esters wax, 2-octyldodecanol, polysorbate 60, purified water, sodium phosphate monobasic, sorbitan monostearate
Call 1-877-753-3935 Monday-Friday 9AM-5PM EST
Clotrimazole
Vaginal Cream, USP 1%
Vaginal Antifungal (with 1 Reusable Applicator
7-Day Treatment
Cures most vaginal east infections
One 1.59 oz (45 g) Tube of Vaginal Cream (1%)
and 1 reusable plastic applicator (7-Day Therapy)
Distributed by:
Pharmacy Value Alliance, LLC
407 East Lancaster Avenue,
Wayne, Pa 19087
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68016-414-00 | GM - Gram | 68016-414 | 56d97e4f-d3a6-42f9-ac02-b4b04e554612 | 1 | 2022-06-06 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CLOTRIMAZOLE | ACTIVE INGREDIENT | G07GZ97H65 | 2 | |
| CLOTRIMAZOLE | ACTIVE MOIETY | G07GZ97H65 | 2 | |
| BENZYL ALCOHOL | INACTIVE INGREDIENT | LKG8494WBH | 2 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 2 | |
| CETYL ESTERS WAX | INACTIVE INGREDIENT | D072FFP9GU | 2 | |
| OCTYLDODECYL STEARATE | INACTIVE INGREDIENT | K6F16QGO28 | 2 | |
| POLYSORBATE 60 | INACTIVE INGREDIENT | CAL22UVI4M | 2 | |
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | INACTIVE INGREDIENT | 593YOG76RN | 2 | |
| SORBITAN MONOSTEARATE | INACTIVE INGREDIENT | NVZ4I0H58X | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68016-414 | 68016-414-00 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CLOTRIMAZOLE | G07GZ97H65 | ACTIB |
| BENZYL ALCOHOL | LKG8494WBH | IACT |
| CETOSTEARYL ALCOHOL | 2DMT128M1S | IACT |
| CETYL ESTERS WAX | D072FFP9GU | IACT |
| OCTYLDODECANOL | 461N1O614Y | IACT |
| POLYSORBATE 60 | CAL22UVI4M | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | IACT |
| SORBITAN MONOSTEARATE | NVZ4I0H58X | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | 18 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SUSPENSION / ORAL | 104 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | TABLET, COATED / ORAL | NA | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / ORAL | 1500 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRASYNOVIAL | 13 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / OPHTHALMIC | 4 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SUSPENSION / OPHTHALMIC | 0.04 %w/w | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | CREAM / TOPICAL | 225 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRA-ARTICULAR | 14 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRALESIONAL | 14 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SUSPENSION / INTRAMUSCULAR | 40 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | LOTION / TOPICAL | 5 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | TABLET / ORAL | 1.06 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SOLUTION / INTRAVENOUS | 242 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, EMULSION / SUBCUTANEOUS | 225 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SUSPENSION / ORAL | 100 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SUPPOSITORY / VAGINAL | NA | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRA-ARTERIAL | 0.9 %w/v | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | EMULSION / ORAL | 20 mg/1ml | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 15.55 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | SUPPOSITORY / VAGINAL | NA | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SOLUTION / INTRAMUSCULAR | 54 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION/ DROPS / OPHTHALMIC | 8 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SPRAY, METERED / NASAL | 5 mg/1ml | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, EMULSION / INTRAMUSCULAR | 225 mg | ||
| SORBITAN MONOSTEARATE | SORBITAN MONOSTEARATE | NVZ4I0H58X | CREAM / TOPICAL | 177 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / ORAL | 10.06 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SUSPENSION / INTRA-ARTICULAR | 40 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SHAMPOO / TOPICAL | 1.25 %w/w | ||
| SORBITAN MONOSTEARATE | SORBITAN MONOSTEARATE | NVZ4I0H58X | SPRAY / TOPICAL | 4.58 %w/w | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRAVITREAL | 0.86 %w/v | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | GEL / TOPICAL | 185 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | CREAM / VAGINAL | 1 %w/w | ||
| CETYL ESTERS WAX | CETYL ESTERS WAX | D072FFP9GU | CREAM / TOPICAL | 10.3 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SUPPOSITORY / RECTAL | 129 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / SOFT TISSUE | 13 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | LOTION / TOPICAL | 4000 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2 mg | ||
| SORBITAN MONOSTEARATE | SORBITAN MONOSTEARATE | NVZ4I0H58X | SOLUTION / TOPICAL | NA | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | TABLET, DELAYED RELEASE / ORAL | 35 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | LIQUID / INTRAVENOUS | 1.04 %w/v | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / SOFT TISSUE | 23 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRALESIONAL | 23 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | SUSPENSION / ORAL | 125 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRACAVITARY | 0.01 ml | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRAMUSCULAR | 1000 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRAMUSCULAR | 13 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / INTRAVESICAL | 0.12 mg | ||
| CETYL ESTERS WAX | CETYL ESTERS WAX | D072FFP9GU | POWDER, FOR SUSPENSION / ORAL | NA | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 8.4 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | GEL / VAGINAL | 100 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | TABLET, EXTENDED RELEASE / ORAL | 800 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / TOPICAL | 0.46 %w/v | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | SPRAY / TOPICAL | 1 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SUSPENSION / INTRALESIONAL | 20 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | AEROSOL, FOAM / TOPICAL | 30 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | TABLET, DELAYED RELEASE / ORAL | 2.31 mg | ||
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 15.55 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074165-001 | CLOTRIMAZOLE | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074165-001 | CLOTRIMAZOLE | 1% | CREAM / VAGINAL | RS | 1993-07-16 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5d7b8648-cf9d-4c61-a69a-3532b3b8954b | c9f591e2-ad16-44ac-b5e0-a5f3871d96bf | 2024-10-09 | Warnings | 5d7b8648-cf9d-4c61-a69a-3532b3b8954b c9f591e2-ad16-44ac-b5e0-a5f3871d96bf |
Adverse event summaries are temporarily unavailable. Other product information remains available.